Linda Burkly
Fortune : 202 076 $ au 30/06/2026
Fortune : 202 076 $ au 30/06/2026
Linda C.
Burkly is Chief Scientific Officer & Executive VP at Editas Medicine, Inc. since 2023.
Formerly, Dr. Burkly was Vice President & Senior Distinguished Investigator at Biogen, Inc. from 2014 to 2022.
Education includes an undergraduate degree from Fairfield University and a doctorate from Tufts University.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
EDITAS MEDICINE, INC. 0,04 % | 28/07/2026 | 62 369 ( 0,04 % ) | 202 076 $ | 30/06/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| EDITAS MEDICINE, INC. | Directeur Technique/Scientifique/R&D | 24/07/2023 |
| Sociétés | Poste | Fin |
|---|---|---|
| BIOGEN INC. | Corporate Officer/Principal | 01/01/2022 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 4 |
|---|---|
Biogen, Inc.
Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
Fairfield University
Fairfield University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Tufts University
Tufts University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Editas Medicine, Inc.
Editas Medicine, Inc. BiotechnologyHealth Technology Manufactures gene editing medicines | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national